Lb Pharmaceuticals (LBRX) Cash & Equivalents (2024 - 2026)

Lb Pharmaceuticals has reported Cash & Equivalents for 3 years, with the latest figure at $320.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents changed N/A year-over-year to $320.7 million; the trailing twelve-month figure through Mar 2026 stood at $320.7 million (changed N/A YoY), and the FY2025 full-year result was $250.2 million, up 988.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $320.7 million, up from $250.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $320.7 million in Q1 2026, with the low at $23.0 million in Q4 2024.
• Average Cash & Equivalents over 3 years is $215.9 million, with a median of $260.0 million recorded in 2025.
• Peak annual rise in Cash & Equivalents reached 988.75% in 2025, while the deepest fall reached 988.75% in 2025.
• Tracing LBRX's Cash & Equivalents over 3 years: stood at $23.0 million in 2024, then surged by 988.75% to $250.2 million in 2025, then gained by 28.18% to $320.7 million in 2026.
• The last three Cash & Equivalents figures came in at $320.7 million (Q1 2026), $250.2 million (Q4 2025), and $269.7 million (Q3 2025), per Business Quant data.

Peer Comparison